Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RKTO vs PHIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PHIO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 8–1 Matrix Metrics)

PHIO Overall Winner 6-Pillar Tally: RKTO 1 – 3 PHIO (2 Tie) Matrix Metrics: RKTO 1 – 8 PHIO

As of Nov 20, 2026, Phio Pharmaceuticals Corp. (PHIO) is the stronger overall head-to-head candidate over RKTO (RKTO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RKTO carries a Unified Composite Score of 44.2/100 (HOLD) at $0.30 (N/M Forward P/E, N/A operating margin), whereas PHIO carries 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RKTO currently prints a higher short-term Unified Composite Score (44.2/100 HOLD vs. PHIO 41.2/100 SELL), PHIO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: RKTO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.8); meanwhile PHIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RKTO vs PHIO
RKTO US Equity
RKTO
Institutional Equity
$0.30
+6.11% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.16β · 63% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.1%), weak momentum, RSI 22
RSI-14: 21.8 · SMA20: $0.40 · SMA50: $0.56
PHIO NASDAQ Head-to-Head Winner
Phio Pharmaceuticals Corp. Common Stock
Pharmaceutical Preparations
$0.66
-8.25% 1D
Market Cap $8.5M
TTM Revenue N/A
Forward P/E 0.3x
Beta / 30D Vol 1.07β · 57% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 23
RSI-14: 22.7 · SMA20: $0.81 · SMA50: $0.91

6-Pillar Scorecard Institutional Category Breakdown (RKTO 1 – 3 PHIO)

Columns: Metric · RKTO · PHIO
1. Valuation Multiples PHIO
Forward P/E N/M 0.3x
Trailing P/E N/M 0.3x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PHIO
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $8.5M
3. Profitability & Quality PHIO
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -159.0%
4. Balance Sheet & Cash Flow RKTO
Cash Generation (TTM) N/A -$11M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.72 Book/Sh · -159.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RKTO (1) vs PHIO (8)
Institutional Metric RKTO PHIO Criterion Row Edge
Market Capitalization
Scale
N/A $8.5M Larger Scale PHIO
Trailing P/E Ratio
Valuation
N/M 0.3x Lower Multiple PHIO
Forward P/E Ratio
Valuation
N/M 0.3x Lower Multiple PHIO
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth PHIO
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin PHIO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin PHIO
Return on Equity (ROE)
Capital Efficiency
N/A -159.0% Higher ROE PHIO
52-Week Range Position
Momentum
2% ($0–$2) 1% ($1–$2) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.16β · 63% Vol 1.07β · 57% Vol Lower Realized Risk PHIO
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite RKTO
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$11M ($0.72 Book/Sh · -159.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PHIO +19.42 pp
RKTO: -44.23% · PHIO: -24.81%
3M Horizon PHIO +15.84 pp
RKTO: -59.77% · PHIO: -43.93%
6M Horizon PHIO +40.07 pp
RKTO: -82.53% · PHIO: -42.46%
1Y Horizon PHIO +40.07 pp
RKTO: -82.53% · PHIO: -42.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RKTO vs PHIO. Trailing 12-month operating profitability (RKTO N/A vs PHIO 0.0%) and valuation multiples (RKTO N/M vs PHIO 0.3x Forward P/E) are benchmarked directly in Pillar 4 below.

RKTO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
PHIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-159.0% · 0.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RKTO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RKTO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PHIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RKTO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PHIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $8.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RKTO vs PHIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Phio Pharmaceuticals Corp. (PHIO) is the stronger overall head-to-head candidate over RKTO (RKTO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RKTO carries a Unified Composite Score of 44.2/100 (HOLD) at $0.30 (N/M Forward P/E, N/A operating margin), whereas PHIO carries 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RKTO currently prints a higher short-term Unified Composite Score (44.2/100 HOLD vs. PHIO 41.2/100 SELL), PHIO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: RKTO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.8); meanwhile PHIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PHIO leads the Growth & Scale pillar: RKTO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PHIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RKTO generates N/A in USD-normalized revenue versus N/A for PHIO. In operating R&D and SG&A reinvestment, RKTO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PHIO.

PHIO screens cheaper on headline valuation multiples. RKTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PHIO trades at 0.3x Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RKTO (N/A ROE) versus PHIO (-159.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RKTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.16β · 63% Vol realized risk). By comparison, PHIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.